Entering text into the input field will update the search result below

ImmunoGen GAAP EPS of -$0.24 misses by $0.03, revenue of $14.2M misses by $1.98M, reiterates FY guidance

Jul. 29, 2022 6:34 AM ETImmunoGen, Inc. (IMGN) StockBy: Deepa Sarvaiya, SA News Editor
  • ImmunoGen press release (NASDAQ:IMGN): Q2 GAAP EPS of -$0.24 misses by $0.03.
  • Revenue of $14.2M (-16.2% Y/Y) misses by $1.98M.
  • ImmunoGen had $373.9 million in cash and cash equivalents as of June 30, 2022, compared with $478.8 million as of December 31, 2021.
  • FINANCIAL GUIDANCEImmunoGen’s financial guidance for 2022 remains unchanged; the Company continues to expect:

  • revenues between $75 million and $85 million vs consensus of $84.68M;
  • operating expenses between $285 million and $295 million; and
  • cash and cash equivalents at December 31, 2022 to be between $245 million and $255 million.
  • Shares +4.76% PM.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
IMGN--
ImmunoGen, Inc.